Main Findings on Therapeutic Management of Lower Extremity ArteryDisease

  title={Main Findings on Therapeutic Management of Lower Extremity ArteryDisease},
  author={Gabriella Ricci and Santa Carbonara and Marco Matteo Ciccone},
Atherosclerosis can involve several areas, resulting in various degrees of the vascular disease. Patients with peripheral arterial disease of the lower limbs (LEAD, lower extremity artery disease) represent a significant percentage of the vascular disease population. Therefore, the main objective of physicians who examine a patient with LEAD is to intervene on the risk factors (common to all cardiovascular diseases) using different therapeutic approaches: exercise, specific drugs and ultimately… 

Tables from this paper

Review on Vascular Diseases & Its Treatment
Vascular illness is an obsessive condition of expansive and medium solid corridors and is activated by endothelial cell dysfunction, and can be recommended by your specialist to lower cholesterol levels, to diminish or control hypertension, to enhance blood stream, and to control glucose in diabetes.


Critical limb ischemia
Surgical treatment is also indicated for failures of endovascular therapy, which may include early technical failures or later occlusion after placement of stents or other interventions.
Diagnosis and management of lower limb peripheral arterial disease: summary of NICE guidance
This article summarises some of the most recent recommendations from the National Institute for Health and Clinical Excellence (NICE) on the management of peripheral arterial disease.
Critical limb ischemia and its treatments: a review.
Critical limb ischemia (CLI) encompasses the most extreme end of the peripheral artery disease (PAD) spectrum leading to significant morbidity and mortality, requiring a thoughtful and multidisciplinary approach, risk-benefit analysis and treatment of comorbid conditions.
Clinical trials of adult stem cell therapy for peripheral artery disease.
Preclinical studies indicate that a variety of stem cell therapies provide growth factors and cytokines for therapeutic angiogenesis, but mechanisms of therapeutic effect, if any, are not understood.
Arterial gene transfer for therapeutic angiogenesis in patients with peripheral artery disease.
The purpose of this clinical protocol is to document the safety of therapeutic angiogenesis achieved by percutaneous catheter-based delivery of the gene encoding vascular endothelial growth factor (VEGF) in patients with PAD; and investigate the bioactivity of this strategy to relieve rest pain and heal ischemic ulcers of the lower extremities.
Intermittent pneumatic compression for the treatment of lower extremity arterial disease: a systematic review
It is evident that an intermittent pneumatic compression program appears promising and may be used in patients with severe peripheral arterial disease who are not candidates for revascularization using surgery or percutaneous angioplasty.
Angiogenic growth factors in the treatment of peripheral arterial disease.
Both experimental and clinical studies have demonstrated that topical AGF gene therapy results in improved peripheral vasculature and alleviation of symptoms, but most clinical work is limited to small patient series and the long-term safety and efficacy are still unclear.
VEGF gene therapy for coronary artery disease and peripheral vascular disease.
Therapeutic angiogenesis for peripheral artery disease: stem cell therapy.
This review summarises the data from experimental and clinical studies related to peripheral arterial disease and cellular therapy.
Treatment of hypertension in peripheral arterial disease.
  • D. LaneG. Lip
  • Medicine
    The Cochrane database of systematic reviews
  • 2009
Evidence on various anti-hypertensive drugs in people with PAD is poor so it is unknown whether significant benefits or risks accrue from their use, and lack of data specifically examining outcomes in PAD patients should not detract from the compelling evidence of the benefit of treating hypertension and lowering blood pressure.